[{"id":"df1bfe68-ecc9-44e8-b084-26686faa2f5d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04324372","created_at":"2021-01-18T20:56:59.555Z","updated_at":"2024-07-02T16:36:05.550Z","phase":"Phase 1","brief_title":"Clinical Study of HEC68498 in Patients With Advanced Refractory Solid Tumors","source_id_and_acronym":"NCT04324372","lead_sponsor":"Sunshine Lake Pharma Co., Ltd.","biomarkers":" HER-2 • PIK3CA • PTEN","pipe":" | ","alterations":" HER-2 negative • PIK3CA mutation • PTEN mutation","tags":["HER-2 • PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PIK3CA mutation • PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HEC68498"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 02/27/2019","start_date":" 02/27/2019","primary_txt":" Primary completion: 02/26/2021","primary_completion_date":" 02/26/2021","study_txt":" Completion: 03/26/2021","study_completion_date":" 03/26/2021","last_update_posted":"2022-08-12"}]